Core Viewpoint - The FDA's approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) represents a significant advancement in regenerative medicine and highlights the potential of MSC therapies [1][2] Company Overview - Pluri Inc. is focused on developing innovative cell-based technologies and has a proprietary 3D cell-expansion platform that enables scalable and robust cell-based therapies [2][4] - The company aims to address critical unmet medical needs through its advanced cell therapy product candidates, including PLacental eXpanded cells for various indications [3][4] Industry Impact - The FDA approval is seen as a milestone not only for Mesoblast but for the entire field of cellular medicine, emphasizing the transformative potential of MSC therapies in healthcare [2][3] - Regenerative medicine is positioned to shift the healthcare paradigm from managing chronic conditions to enabling true healing and regeneration, potentially improving patient outcomes and creating more sustainable healthcare systems [2][3] Future Aspirations - Pluri is committed to expanding the therapeutic boundaries of cell-based solutions and accelerating the development of MSC-based therapies globally [3][4] - The company envisions a future where cell-based technologies can transform lives across a spectrum of diseases, leveraging its expertise to pioneer new treatments [3]

Memorandum of Understanding has been signedNEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it has entered into a Memorandum of Understanding (MOU) with Pluri Inc. (NASDAQ: PLUR) through its wholly owned subsidiary ("Pluri"), an established global leader in the development and manufacturing of cell-based therapeutics, to manufacture NurOwn® for use in BrainStorm's planned P ...

Core Insights - Plurilock Security Inc. is positioned for growth in the cybersecurity sector, focusing on expanding its service offerings and client base while enhancing operational efficiency [4][11][12]. Group 1: Corporate Developments - The company received a three-year contract worth US$814,000 to provide cloud security services to a major laboratory data and advisory firm [3]. - Plurilock has announced over US$20 million in new sales orders since the beginning of 2024, indicating strong demand for its services [11][12]. - The company has streamlined operations and integrated its four key acquisitions, achieving annual savings of US$2 million, which are being reinvested into higher-margin services [5][6]. Group 2: Strategic Focus - Plurilock's strategic plan emphasizes converting one-time engagements into recurring managed services, thereby enhancing client retention and profitability [6][28]. - The launch of the Critical Services division in February 2024 aims to address urgent cybersecurity challenges and improve organizational efficiency [13][14]. - The company is actively recruiting new sales staff to bolster its sales efforts, particularly in high-margin Critical Services and SaaS offerings [26]. Group 3: Financial Position - Plurilock completed a financing round that raised US$5.5 million, which will support the growth of its Critical Services division and expand its sales team [24][27]. - The company achieved revenue of US$70.4 million in 2023, reinforcing its status as a trusted cybersecurity provider in North America and NATO countries [23]. - Plurilock is focused on achieving breakeven and converting existing client relationships into long-term managed services contracts, which will generate stable revenue streams [28].

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic cells for ALS and diabetes treatments. PluriCDMO™, launched earlier this year, leverages Pluri's 47,000 squar ...

Company Overview - Pluri Inc is a leading biotechnology company that transforms cells into solutions promoting global wellbeing and sustainability [1] - The company operates in regenerative medicine, foodtech, and agtech, and offers CDMO services [7] - Pluri's proprietary 3D cell expansion technology is patented, scalable, cost-effective, and consistent [7] Strategic Collaboration - Pluri has entered a proof of concept agreement with a leading international agriculture corporation to boost global vegetable supply, streamline supply chains, and combat climate change [1] - The collaboration leverages Pluri's expertise in cell-expansion technologies and cellular agriculture, combined with the partner's global presence and knowledge of the food industry [10] - The partnership aims to minimize environmental impact, foster food security, and build sustainable, high-quality agricultural solutions [5] Market Context - The global vegetable farming market is valued at $1.3 trillion and is expected to grow to $1.6 trillion by 2029, with a CAGR of 3.4% from 2024 to 2029 [6] - The global population is projected to increase from 7.5 billion to 8.6 billion by 2030 and 11.2 billion by the end of the century, driving the need for alternative agricultural technologies [2] Business Strategy - Pluri's strategy involves collaborating with leading global companies across industries to generate revenue through innovative projects [2] - The company believes this collaboration has the potential to positively impact the vegetable market and create significant shareholder value [2] Technology and Innovation - Pluri's 3D cell expansion technology is expected to benefit farmers worldwide by enabling sustainable, high-quality agricultural solutions [5] - The company is pioneering a biotech revolution to address challenges in medicine, climate change, food scarcity, and animal cruelty [7]

"Ever After Foods' unique and innovative production platform empowered the change to our business model. The shift to a technology enabler will allow us to serve more players in the value chain," said Eyal Rosenthal, Chief Executive Officer of Ever After Foods."Securing funding from new global partners is a testament to our team's tireless dedication to solving the primary production barriers for the next step toward a more sustainable meat industry. In addition to the funding, working with new partners in ...

Core Insights - The joint investment in Ever After Foods highlights the importance of collaboration in creating a sustainable global food system, with a focus on cultivated meat technology [1][14] - Ever After Foods aims to revolutionize meat production by providing ethical and sustainable cultivated meat products at scale, leveraging Pluri's advanced technology [7][10] Investment and Financials - A $10 million funding round from U.S. and EU strategic investors will enhance Ever After Foods' capabilities in producing cultivated meat, fish, and seafood, addressing scalability challenges in the industry [14] - The investment round includes participation from global corporates and Tnuva, indicating strong confidence in Ever After Foods' business model and technology [9][11] Technology and Innovation - Ever After Foods utilizes Pluri's patented 3D cell expansion technology, which allows for up to six times more protein and 700 times more lipids from each cell compared to other platforms, enhancing nutritional and flavor profiles [5][10] - The company has developed a B2B version of its technology that significantly reduces production costs by over 90% while increasing productivity [10] Market Position and Strategy - Ever After Foods is positioned as a leading technology enabler in the cultivated meat sector, with plans to expand its reach and impact in international markets [9][15] - The collaboration with Tnuva and other global partners is expected to deepen industry networks and accelerate growth in the cultivated meat space [15]

As part of Pluri's previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund manufacturing, in-vitro, and in-vivo studies of Pluri's cell therapy PLX-R18 is designed to be a first in class, effective treatment for ionizing radiation injuries that could be anticipated in the wake of a large-scale nuclear incident Work during the contract period is expected to make fur ...

Core Insights - Pluri Inc. is advancing the development of PLX-R18 as a potential treatment for hematopoietic acute radiation syndrome (H-ARS) in collaboration with the U.S. Department of Defense and the National Institute of Allergy and Infectious Diseases [1][7] - PLX-R18 has shown significant efficacy in increasing survival rates and recovery of blood cell counts in both animal and human studies [1][2] - The company has secured a $4.2 million contract with NIAID, with $1.4 million allocated for the second year to further develop PLX-R18 [7] Company Overview - Pluri Inc. is a biotechnology company focused on creating cell-based products for various applications, including regenerative medicine and food technology [4] - The company utilizes a patented 3D cell expansion system to produce scalable and cost-effective cell-based solutions [4] Product Development - PLX-R18 is designed to treat injuries from ionizing radiation, particularly in scenarios involving nuclear incidents [7][8] - The FDA has granted PLX-R18 Orphan Drug Designation and approved an Investigational New Drug application for its use in H-ARS [8] Clinical Results - In animal studies, PLX-R18 increased survival rates from 29% to 97% when administered post-radiation exposure [1] - Human trials indicated that patients treated with PLX-R18 experienced significant increases in platelet, hemoglobin, and neutrophil levels, along with a reduction in transfusion needs [2]

Core Insights - Pluri Inc. has announced a strategic collaboration with Wilk Technologies to develop a unique medical food for the elderly using components of breast milk [1][3] - The collaboration aims to leverage Pluri's 3D cell-expansion technology alongside Wilk's expertise in cultured milk products, targeting the growing demand for medical foods due to an aging population and chronic illnesses [2][3] Company Overview - Pluri Inc. is focused on creating cell-based products for commercial use, utilizing a patented 3D cell expansion system to address challenges in medicine, food scarcity, and sustainability [4] - Wilk Technologies specializes in sustainable dairy production, particularly cultured human breast milk and cow milk ingredients, with a commitment to reducing carbon footprints in the dairy industry [5] Market Potential - The global elderly nutrition market is currently valued at $25.2 billion and is projected to reach $39.7 billion within the next decade, indicating significant growth potential for medical food products [6]